Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720711 | 0.90 | GAA (0.73) | GAATHRBATML3MBTL1SMN1; SMN2 | |
| SCHEMBL9675422 | 0.90 | ALDH1A1 (0.64) | GAATHRBATML3MBTL1ALDH1A1 | |
| SCHEMBL9675197 | 0.86 | SMN1; SMN2 (0.59) | GAAL3MBTL1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL9214032 | 0.83 | GAA (0.62) | GAATHRBATML3MBTL1SMN1; SMN2 | |
| SCHEMBL11936428 | 0.81 | SMN1; SMN2 (0.54) | GAAL3MBTL1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3055942 | 0.81 | GAA (0.60) | GAATHRBATML3MBTL1SMN1; SMN2 | |
| SCHEMBL6215242 | 0.80 | ALDH1A1 (0.71) | SMN1; SMN2ALDH1A1POLBHTT | |
| SCHEMBL631512 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL16025051 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL14348062 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | GAA 505/4885THRB 4727/4885ATM 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.